MARLBOROUGH, Mass.,
Oct. 7, 2015 /PRNewswire/
-- Boston Scientific (NYSE: BSX) today announced key data
presentations spanning its broad interventional cardiology,
structural heart and peripheral interventions portfolios to be
shared at the 27th Transcatheter Cardiovascular Therapeutics (TCT)
meeting, the annual scientific symposium of the Cardiovascular
Research Foundation, to be held in San
Francisco October 11-15.
Scheduled abstracts will evaluate Boston Scientific technologies
for treating patients with a range of cardiovascular diseases, and
explore topics including:
- The costs associated with bleeding complications due to
warfarin versus the WATCHMAN™ Left Atrial Appendage Closure Device,
which was approved by the U.S. Food and Drug Administration (FDA)
in March, 2015 to reduce the risk of stroke in people with
non-valvular atrial fibrillation;
- Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System
safety and efficacy data from the REPRISE I and REPRISE II studies;
and
- Long-term safety and efficacy data out to five years with the
PROMUS Element® Platinum Chromium Everolimus-Eluting
Stent.
Earlier this week, the company received FDA approval of the
SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES)
for the treatment of patients with coronary artery disease (CAD).
The commercialization of the first and only BP-DES in the U.S.
reinforces the depth and breadth of the Boston Scientific
innovative cardiology portfolio.
"The recently approved and first-to-market WATCHMAN Device and
SYNERGY Stent are opening doors for cardiologists to treat patients
with non-valvular atrial fibrillation and coronary artery disease
in new and innovative ways," said Keith
Dawkins, M.D., global chief medical officer, Boston
Scientific. "In addition to exploring these prevalent health
conditions at TCT, we will also share data crucial to the
advancement of device-related treatment for patients suffering from
aortic valve disease and peripheral arterial disease."
ABSTRACTS OF INTEREST (listed chronologically within
product categories)
Coronary Stents
- Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY
Update: Dean Kereiakes, M.D., will
lead a discussion on the SYNERGY Stent during the Metallic
Drug-Eluting Stents: Controversies with Today's Technology
Symposium on Sunday, October 11 from
1:05-1:13 p.m. in Moscone West, 3rd
Floor, Rooms 3001-3005.
- Two-Year Outcomes in 'Real-World Patients' Treated with a
Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent, in the
PROMUS Element Plus US Post-Approval Study (PE-Plus PAS):
David Kandzari, M.D., will present
on Tuesday, October 13 at
3:30 p.m. in Rooms 3014-3018.
- Final 5-Year Outcomes Following Implantation of the PROMUS
Element Platinum Chromium Everolimus-Eluting Stent in De Novo
Coronary Artery Lesions in Small Vessels (SV) and Long Lesions
(LL): Results of the PLATINUM Small Vessel and Long Lesion trials:
Paul Teirstein, M.D., will present
during the poster session on Tuesday,
October 13 from 4 -6 p.m. in
the Poster Hall (West Building).
WATCHMAN Device
- Cost Analysis of Bleed Complications from Two Stroke Prevention
Strategies in Non-Valvular Atrial Fibrillation: Left Atrial
Appendage: Matthew Price, M.D., will
present on Tuesday, October 13 at
3:30 p.m. Check final TCT agenda for
presentation location.
Structural Heart
- First Report of Three-Year Outcomes with the Repositionable and
Fully Retrievable Lotus Aortic Valve Replacement System: Results
from the REPRISE I Feasibility Study: Prof. Ian Meredith, Ph.D., will present during the
poster session on Tuesday, October 13
from 4-6 p.m. in the Poster Hall
(West Building).
- Two-Year Outcomes with the Fully Repositionable and Retrievable
Lotus™ Transcatheter Aortic Replacement Valve in 120 High-Risk
Surgical Patients with Severe Aortic Stenosis: Results from the
REPRISE II CE-Mark Study: Prof. Ian
Meredith, Ph.D., will present on Thursday, October 15 at 12:45 p.m. in Room Moscone South, Lower Level,
Room 104.
Peripheral Interventions
- Bipolar Radiofrequency Renal Denervation with the Vessix
Catheter in Patients with Resistant Hypertension: 2-year Results
from the REDUCE-HTN trial: Prof. Horst
Sievert, M.D., Ph.D., will present during the poster session
on Tuesday, October 13, 2015 from
4 -6 p.m. in the Poster Hall (West
Building).
All programs are listed in Pacific Daylight Time and will take
place at the Moscone Convention Center unless otherwise noted. For
additional product information, visit Boston Scientific at booth
#1225.
Lotus is an investigational device and not available for sale in
the U.S.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
CONTACTS
Media:
Trish Backes
Boston Scientific Corporation
651-582-5887 (office)
Trish.Backes@bsci.com
Investors:
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-tct-2015-300156032.html
SOURCE Boston Scientific Corporation